Dupilumab Treatment Up to 5 Years Shows No Clinically Meaningful Changes in Laboratory Parameters in Adults with Moderate-to-Severe Atopic Dermatitis

Authors

Mette Soendergaard Deleuran
Robert Bissonnette (ORCID: https://orcid.org/0000-0001-5927-6587)
M. Bastian
de Bruin-Weller
Faisal A. Khokhar
Michael Van Spall
Ryszard Galus
Eric L. Simpson
Zhen Chen
Elena Avetisova
Takeshi Nakahara
Anna Coleman

Institutions

Kyushu University (JP)
Oregon Health & Science University (US)
Regeneron (United States) (US)
Utrecht University (NL)
Medical University of Warsaw (PL)
Aarhus University Hospital (DK)
University Medical Center Utrecht (NL)
Sanofi (United States) (US)
Innovaderm (Canada) (CA)
Sanofi (Germany) (DE)

Publication Details

Journal: Advances in Therapy
Published: 2026-01-21
DOI: https://doi.org/10.1007/s12325-025-03458-3
Primary Topic: Dermatology and Skin Diseases
Type: article
Field-Weighted Citation Impact: 0.00

Controls

|||

ALL TIME

JAN

FEB

MAR

APR

MAY

JUN

JUL

AUG

SEP

OCT

article

Dupilumab Treatment Up to 5 Years Shows No Clinically Meaningful Changes in Laboratory Parameters in Adults with Moderate-to-Severe Atopic Dermatitis

Mette Soendergaard Deleuran, Robert Bissonnette, M. Bastian, de Bruin-Weller et al.

Jan 21, 2026

Advances in Therapy

Dermatology and Skin Diseases

article

Dupilumab Treatment Up to 5 Years Shows No Clinically Meaningful Changes in Laboratory Parameters in Adults with Moderate-to-Severe Atopic Dermatitis

Mette Soendergaard Deleuran, Robert Bissonnette, M. Bastian, de Bruin-Weller, Faisal A. Khokhar, Michael Van Spall, Ryszard Galus, Eric L. Simpson, Zhen Chen, Elena Avetisova, Takeshi Nakahara, Anna Coleman

January 21, 2026article en

Abstract

No abstract available for this paper.

Advances in TherapyVol. 43(3)

Kyushu University (JP), Oregon Health & Science University (US), Regeneron (United States) (US), Utrecht University (NL), Medical University of Warsaw (PL), Aarhus University Hospital (DK), University Medical Center Utrecht (NL), Sanofi (United States) (US), Innovaderm (Canada) (CA), Sanofi (Germany) (DE)

Openalex Percentile: Top 82%

Dermatology and Skin Diseases

DOI Open Access PDF OpenAlex

AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.